Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Parkinson's disease cost Europe €22.8 billion (~$26.5B) in 2019, with the bulk driven by direct medical expenses and informal caregiving. An aging population and better diagnostics are pushing prevalence higher, raising concerns about future economic strain. Experts say early diagnosis and optimized treatment pathways could help curb downstream costs.
Parkinson's disease (PD) carried a staggering €22.8 billion (~$26.5 billion) price tag across Europe in 2019, according to a sweeping new analysis published in Movement Disorders. The study — the first major European cost evaluation since 2010 — covered 43 countries and found that the burden falls not just on healthcare systems, but heavily on families and society at large.
Contrary to popular assumption, medical bills aren't the biggest driver. Informal care — think unpaid support from family and friends — and progression-related disability costs are dominant factors, researchers say. That reframes how policymakers should think about investing in early diagnosis and optimized treatment: reducing disease burden upstream can generate real savings downstream.
By the Numbers:
Why it matters: With an aging European population and improving diagnostic tools, PD prevalence — and its costs — will only climb. Researchers are urging policymakers to strengthen healthcare infrastructure, expand access to caregiving support, and fund health-economic research to stay ahead of the curve.
